ArticleScience translational medicine2014

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

Leyuan Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.